TAVRinTAVRはすごいなあ。
RT @S10CF: そろそろTAVR in TAVR症例報告あるんじゃないかと思っていたけど、やっぱり報告あった。 TAVR後の偶発的な弁不具合に対して再度TAVRを施行して、212例で1年生存率は86.5%。 SAVRは減っていく方向かな https://t.co/lB…
RT @S10CF: そろそろTAVR in TAVR症例報告あるんじゃないかと思っていたけど、やっぱり報告あった。 TAVR後の偶発的な弁不具合に対して再度TAVRを施行して、212例で1年生存率は86.5%。 SAVRは減っていく方向かな https://t.co/lB…
RT @S10CF: そろそろTAVR in TAVR症例報告あるんじゃないかと思っていたけど、やっぱり報告あった。 TAVR後の偶発的な弁不具合に対して再度TAVRを施行して、212例で1年生存率は86.5%。 SAVRは減っていく方向かな https://t.co/lB…
RT @S10CF: そろそろTAVR in TAVR症例報告あるんじゃないかと思っていたけど、やっぱり報告あった。 TAVR後の偶発的な弁不具合に対して再度TAVRを施行して、212例で1年生存率は86.5%。 SAVRは減っていく方向かな https://t.co/lB…
RT @S10CF: そろそろTAVR in TAVR症例報告あるんじゃないかと思っていたけど、やっぱり報告あった。 TAVR後の偶発的な弁不具合に対して再度TAVRを施行して、212例で1年生存率は86.5%。 SAVRは減っていく方向かな https://t.co/lB…
RT @S10CF: そろそろTAVR in TAVR症例報告あるんじゃないかと思っていたけど、やっぱり報告あった。 TAVR後の偶発的な弁不具合に対して再度TAVRを施行して、212例で1年生存率は86.5%。 SAVRは減っていく方向かな https://t.co/lB…
そろそろTAVR in TAVR症例報告あるんじゃないかと思っていたけど、やっぱり報告あった。 TAVR後の偶発的な弁不具合に対して再度TAVRを施行して、212例で1年生存率は86.5%。 SAVRは減っていく方向かな https://t.co/lBX7ipf7WU
RT @HeartOTXHeartMD: "Repeat transcatheter aortic-valve replacement (redo- #TAVR) appears to be a reasonable option when transcatheter aort…
RT @HeartOTXHeartMD: "Repeat transcatheter aortic-valve replacement (redo- #TAVR) appears to be a reasonable option when transcatheter aort…
"Repeat transcatheter aortic-valve replacement (redo- #TAVR) appears to be a reasonable option when transcatheter aortic valves fail,” investigators concluded after analyzing “data from the #RedoTAVR registry on 212 patients. #TAVI https://t.co/y9vuZM9ACb
RT @crfshj: Very important paper on re-do #TAVR for failed #THVs in @JACCJournals. 212 patients at 37 sites. 👇 TAVR-in-TAVR take home mes…
RT @GilbertTangMD: Nice paper on #redoTAVR after failed #TAVR. @JACCJournals Incidence remains low with good outcomes but highly selected p…
RT @crfshj: Very important paper on re-do #TAVR for failed #THVs in @JACCJournals. 212 patients at 37 sites. 👇 TAVR-in-TAVR take home mes…
RT @GilbertTangMD: Nice paper on #redoTAVR after failed #TAVR. @JACCJournals Incidence remains low with good outcomes but highly selected p…
RT @GilbertTangMD: Nice paper on #redoTAVR after failed #TAVR. @JACCJournals Incidence remains low with good outcomes but highly selected p…
@GuiAttizzaniMD @MarcPPelletier
RT @crfshj: Very important paper on re-do #TAVR for failed #THVs in @JACCJournals. 212 patients at 37 sites. 👇 TAVR-in-TAVR take home mes…
RT @crfshj: Very important paper on re-do #TAVR for failed #THVs in @JACCJournals. 212 patients at 37 sites. 👇 TAVR-in-TAVR take home mes…
RT @GilbertTangMD: Nice paper on #redoTAVR after failed #TAVR. @JACCJournals Incidence remains low with good outcomes but highly selected p…
RT @GilbertTangMD: Nice paper on #redoTAVR after failed #TAVR. @JACCJournals Incidence remains low with good outcomes but highly selected p…
RT @JACCJournals: #TAVR use is increasing in patients w/ longer life expectancy, yet robust data on the durability of transcatheter heart v…
RT @JACCJournals: #TAVR use is increasing in patients w/ longer life expectancy, yet robust data on the durability of transcatheter heart v…
RT @crfshj: Very important paper on re-do #TAVR for failed #THVs in @JACCJournals. 212 patients at 37 sites. 👇 TAVR-in-TAVR take home mes…
RT @GilbertTangMD: Nice paper on #redoTAVR after failed #TAVR. @JACCJournals Incidence remains low with good outcomes but highly selected p…
RT @GilbertTangMD: Nice paper on #redoTAVR after failed #TAVR. @JACCJournals Incidence remains low with good outcomes but highly selected p…
RT @GilbertTangMD: Nice paper on #redoTAVR after failed #TAVR. @JACCJournals Incidence remains low with good outcomes but highly selected p…
RT @crfshj: Very important paper on re-do #TAVR for failed #THVs in @JACCJournals. 212 patients at 37 sites. 👇 TAVR-in-TAVR take home mes…
RT @GilbertTangMD: Nice paper on #redoTAVR after failed #TAVR. @JACCJournals Incidence remains low with good outcomes but highly selected p…
RT @GilbertTangMD: Nice paper on #redoTAVR after failed #TAVR. @JACCJournals Incidence remains low with good outcomes but highly selected p…
RT @GilbertTangMD: Nice paper on #redoTAVR after failed #TAVR. @JACCJournals Incidence remains low with good outcomes but highly selected p…
RT @GilbertTangMD: Nice paper on #redoTAVR after failed #TAVR. @JACCJournals Incidence remains low with good outcomes but highly selected p…
RT @JACCJournals: #TAVR use is increasing in patients w/ longer life expectancy, yet robust data on the durability of transcatheter heart v…
RT @JACCJournals: #TAVR use is increasing in patients w/ longer life expectancy, yet robust data on the durability of transcatheter heart v…
RT @crfshj: Very important paper on re-do #TAVR for failed #THVs in @JACCJournals. 212 patients at 37 sites. 👇 TAVR-in-TAVR take home mes…
RT @GilbertTangMD: Nice paper on #redoTAVR after failed #TAVR. @JACCJournals Incidence remains low with good outcomes but highly selected p…
Nice paper on #redoTAVR after failed #TAVR. @JACCJournals Incidence remains low with good outcomes but highly selected pt group. Watch for higher gradients and coronary obstruction. CT eval is key! Congrats! @tnazifMD @MartyMleon @MayraGuerreroMD and EU ce
RT @JACCJournals: #TAVR use is increasing in patients w/ longer life expectancy, yet robust data on the durability of transcatheter heart v…
RT @crfshj: Very important paper on re-do #TAVR for failed #THVs in @JACCJournals. 212 patients at 37 sites. 👇 TAVR-in-TAVR take home mes…
RT @crfshj: Very important paper on re-do #TAVR for failed #THVs in @JACCJournals. 212 patients at 37 sites. 👇 TAVR-in-TAVR take home mes…
RT @JACCJournals: #TAVR use is increasing in patients w/ longer life expectancy, yet robust data on the durability of transcatheter heart v…
RT @crfshj: Very important paper on re-do #TAVR for failed #THVs in @JACCJournals. 212 patients at 37 sites. 👇 TAVR-in-TAVR take home mes…
RT @JACCJournals: #TAVR use is increasing in patients w/ longer life expectancy, yet robust data on the durability of transcatheter heart v…
RT @JACCJournals: #TAVR use is increasing in patients w/ longer life expectancy, yet robust data on the durability of transcatheter heart v…
RT @crfshj: Very important paper on re-do #TAVR for failed #THVs in @JACCJournals. 212 patients at 37 sites. 👇 TAVR-in-TAVR take home mes…
Very important paper on re-do #TAVR for failed #THVs in @JACCJournals. 212 patients at 37 sites. 👇 TAVR-in-TAVR take home messages: -safe (0.9% cor occlusion, 1.4% stroke, 9% new pacer, ZERO mortality) -effective: at 1 yr gradients ~12 mmHG, symptoms imp
RT @JACCJournals: #TAVR use is increasing in patients w/ longer life expectancy, yet robust data on the durability of transcatheter heart v…
RT @JACCJournals: #TAVR use is increasing in patients w/ longer life expectancy, yet robust data on the durability of transcatheter heart v…
RT @JACCJournals: #TAVR use is increasing in patients w/ longer life expectancy, yet robust data on the durability of transcatheter heart v…
Nice data. But patients should be better informed about the whole thing... https://t.co/YLWj3zrN2W
#TAVR use is increasing in patients w/ longer life expectancy, yet robust data on the durability of transcatheter heart valves is limited. A #JACC study investigates the effectiveness of redo-TAVR for patients experiencing valve dysfunction. https://t.co/O
RT @aelsab: REDO-TAVI published this week in @JACCJournals sheds light on outcomes of tavr-in-tavr and what could be the future of degenera…
RT @aelsab: REDO-TAVI published this week in @JACCJournals sheds light on outcomes of tavr-in-tavr and what could be the future of degenera…
RT @aelsab: REDO-TAVI published this week in @JACCJournals sheds light on outcomes of tavr-in-tavr and what could be the future of degenera…
RT @aelsab: REDO-TAVI published this week in @JACCJournals sheds light on outcomes of tavr-in-tavr and what could be the future of degenera…
REDO-TAVI published this week in @JACCJournals sheds light on outcomes of tavr-in-tavr and what could be the future of degenerated THV’s- happy to contribute to this registry https://t.co/XQgoai3rkH @MayraGuerreroMD @ChetRihal
Repeat Transcatheter Aortic Valve Replacement for Transcatheter Prosthesis Dysfunction | JACC: Journal of the American College of Cardiology https://t.co/UWJNeDWBy9
Repeat Transcatheter Aortic Valve Replacement for Transcatheter Prosthesis Dysfunction. #amchelsinki #tutkimus https://t.co/B0DAEsG600
Repeat Transcatheter Aortic Valve Replacement for Transcatheter Prosthesis Dysfunction https://t.co/q8lTgW1w91
RT @JACCJournals: In patients with long life expectancy, is re-do #TAVR a safe and effective strategy? #JACC investigates: https://t.co/Onr…
RT @JACCJournals: In patients with long life expectancy, is re-do #TAVR a safe and effective strategy? #JACC investigates: https://t.co/Onr…
RT @JACCJournals: In patients with long life expectancy, is re-do #TAVR a safe and effective strategy? #JACC investigates: https://t.co/Onr…
RT @JACCJournals: In patients with long life expectancy, is re-do #TAVR a safe and effective strategy? #JACC investigates: https://t.co/Onr…
RT @JACCJournals: In patients with long life expectancy, is re-do #TAVR a safe and effective strategy? #JACC investigates: https://t.co/Onr…
RT @JACCJournals: In patients with long life expectancy, is re-do #TAVR a safe and effective strategy? #JACC investigates: https://t.co/Onr…
In patients with long life expectancy, is re-do #TAVR a safe and effective strategy? #JACC investigates: https://t.co/OnrpIR1wmT @CHVI85209027 https://t.co/RwfJtHi8VY
Repeat Transcatheter Aortic Valve Replacement for Transcatheter Prosthesis Dysfunction | JACC: Journal of the American College of Cardiology https://t.co/kpyCi8Chtt
RT @Susumu_Manabe: 壊れたTAVR弁にもう一回TAVR.これは安全だから、若い人にもTAVRやりましょうという結論. https://t.co/DaT4xCDEeB
RT @Susumu_Manabe: 壊れたTAVR弁にもう一回TAVR.これは安全だから、若い人にもTAVRやりましょうという結論. https://t.co/DaT4xCDEeB
壊れたTAVR弁にもう一回TAVR.これは安全だから、若い人にもTAVRやりましょうという結論. https://t.co/DaT4xCDEeB